Advertisement

Correction to: A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA

  • Pierre Johansen
  • Barnaby HuntEmail author
  • Neeraj N. Iyer
  • Tam Dang-Tan
  • Richard F. Pollock
Open Access
Correction
  • 81 Downloads

Correction to: Adv Ther  https://doi.org/10.1007/s12325-019-00915-8

The article “A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA”, written by Pierre Johansen, Barnaby Hunt, Neeraj N. Iyer, Tam Dang-Tan, Richard F. Pollock was originally published electronically on the publisher’s internet portal (currently SpringerLink) on November 27, 2018 without Open Access.

The article has now been made Open Access. The copyright of the article changed to © The Author(s) 2018 and the article is forthwith distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any non-commercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and Indicate if changes were made.

The original article has been updated.

Copyright information

© The Author(s) 2019

Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors and Affiliations

  1. 1.Novo Nordisk A/SSøborgDenmark
  2. 2.Ossian Health Economics and Communications GmbHBaselSwitzerland
  3. 3.Novo Nordisk IncPlainsboroUSA

Personalised recommendations